Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial-Reference-Cited by-同舟云学术

Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial

Published:2018-12 Issue:12 Volume:5 Page:e715-e722
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Nachman Sharon,Alvero Carmelita,Teppler Hedy,Homony Brenda,Rodgers Anthony J,Graham Bobbie L,Fenton Terence,Frenkel Lisa M,Browning Renee S,Hazra Rohan,Wiznia Andrew A,Acosta Edward,Douglas Steve,Fry Carrie,Kuryla Samantha,Perdue Lynette,Samson Pearl,Spector Steven,Toye MariPat,Tustin Nancy,Watson Scott,Worrell Carol,Zheng Nan

Funder

NICHD

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference14 articles.

1. Raltegravir with optimized background therapy for resistant HIV-1 infection;Steigbigel;N Engl J Med,2008

2. Safety and efficacy of raltegravir based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial;Lennox;Lancet,2009

3. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMARK studies: final results of two randomised, placebo controlled trials;Eron;Lancet Infect Dis,2013

4. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK;Rockstroh;J Acquir Immune Defic Syndr,2013

5. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1–infected children aged 2 through 18 years;Nachman;Clin Infect Dis,2014

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrase Strand Transfer Inhibitor Use in Children with Perinatal HIV-1 Infection: A Narrative Review;AIDS Research and Human Retroviruses;2023-01-06

2. Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review;Journal of the International AIDS Society;2022-11

3. Integrase inhibitors in children and adolescents: clinical use and resistance;Journal of Antimicrobial Chemotherapy;2022-08-16

4. Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study;Antimicrobial Agents and Chemotherapy;2022-01-18

5. Body image and antiretroviral therapy adherence among people living with HIV: a protocol for a systematic review and meta-analysis;BMJ Open;2021-07